Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty

In October 2023, William Blair wrote that in fiscal year 2024, Catalent anticipates 30% Y/Y growth in nonCOVID biologics revenue, reaching approximately $1.35 billion to$1.80 billion. This growth is primarily fueled by a 60%-plus expansion attributed to Sarepta, translating into an estimated total revenue of nearly $700 million from the collaboration. Despite this, questions remain about Catalent's manufacturing capacity and the future role of Thermo Fisher Scientific Inc TMO as a secondary manufacturer. W ...